| dc.contributor.author | Welsh, Paul | |
| dc.contributor.author | Botha, Shani | |
| dc.contributor.author | Grassia, Gianluca | |
| dc.contributor.author | Sattar, Naveed | |
| dc.contributor.author | Maffia, Pasquale | |
| dc.date.accessioned | 2018-02-16T09:58:14Z | |
| dc.date.available | 2018-02-16T09:58:14Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Welsh, P. et al. 2017. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? British journal of pharmacology, 174(22):3898-3913. [https://doi.org/10.1111/bph.13818] | en_US |
| dc.identifier.issn | 0007-1188 | |
| dc.identifier.issn | 1476-5381 (Online) | |
| dc.identifier.uri | http://hdl.handle.net/10394/26360 | |
| dc.identifier.uri | https://doi.org/10.1111/bph.13818 | |
| dc.identifier.uri | http://onlinelibrary.wiley.com/doi/10.1111/bph.13818/epdf | |
| dc.description.abstract | Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.title | Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? | en_US |
| dc.type | Article | en_US |
| dc.contributor.researchID | 20695241 - Botha, Shani | |
